Literature DB >> 2209323

Influenza infection and diabetes mellitus. Case for annual vaccination.

R J Diepersloot1, K P Bouter, J B Hoekstra.   

Abstract

Herein, epidemiological data on influenza pneumonia and mortality, results of clinical studies, and the outcome of influenza vaccination trials are reviewed. All excess mortality studies that specify for underlying disease list diabetes as one of the major risk factors. During influenza epidemics, death rates among patients with diabetes mellitus may increase by 5-15%. Diabetes mellitus is also mentioned as a risk factor in most clinical studies, making up 3-14% of the patients studied. Even in recent studies, diabetes mellitus is only preceded as a risk factor by cardiovascular disease and chronic pulmonary disorders. To what extent cardiovascular disease and old age contribute to the increased influenza mortality and morbidity in diabetic patients remains unclear. The influence of epidemic influenza on the incidence of diabetic acidosis in combination with an impaired immune response to both Staphylococcus aureus and the influenza virus suggests that diabetes mellitus itself is the main risk factor. It is concluded that all patients with diabetes mellitus should receive annual vaccinations and that, in official recommendations, patients with diabetes mellitus should be mentioned as a separate risk group. Whole-virus vaccines are preferred over subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209323     DOI: 10.2337/diacare.13.8.876

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  Prediction of complicated urinary tract infections in patients with type 2 diabetes: a questionnaire study in primary care.

Authors:  Leonie M A J Venmans; Marian Sloof; Eelko Hak; Kees J Gorter; Guy E H M Rutten
Journal:  Eur J Epidemiol       Date:  2007-01-03       Impact factor: 8.082

2.  Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults.

Authors:  R Valdez; K M Narayan; L S Geiss; M M Engelgau
Journal:  Am J Public Health       Date:  1999-11       Impact factor: 9.308

3.  Increased influenza-related healthcare utilization by residents of an urban aboriginal community.

Authors:  K M Charland; J S Brownstein; A Verma; T Brewer; S Jones; A Gatewood Hoen; D L Buckeridge
Journal:  Epidemiol Infect       Date:  2011-01-20       Impact factor: 2.451

4.  Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients.

Authors:  Bruce Y Lee; Randy M Stalter; Kristina M Bacon; Julie H Y Tai; Rachel R Bailey; Shanta M Zimmer; Michael M Wagner
Journal:  Am J Kidney Dis       Date:  2011-03-10       Impact factor: 8.860

5.  Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose?

Authors:  P C Reading; J Allison; E C Crouch; E M Anders
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

6.  Prospective application of reverse transcriptase polymerase chain reaction for diagnosing influenza infections in respiratory samples from a children's hospital.

Authors:  E C Claas; A J van Milaan; M J Sprenger; M Ruiten-Stuiver; G I Arron; P H Rothbarth; N Masurel
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

7.  Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups.

Authors:  Lise Boey; Eline Bosmans; Liane Braz Ferreira; Nathalie Heyvaert; Melissa Nelen; Lisa Smans; Hanne Tuerlinckx; Mathieu Roelants; Kathleen Claes; Inge Derdelinckx; Wim Janssens; Chantal Mathieu; Johan Van Cleemput; Robin Vos; Corinne Vandermeulen
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

8.  Are annual fluctuations in hip fracture incidence dependent upon the underlying mortality rate?

Authors:  O Johnell; L J Melton; J A Nilsson
Journal:  Osteoporos Int       Date:  1998       Impact factor: 5.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.